GH Research PLC
GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorde… Read more
GH Research PLC (GHRS) - Net Assets
Latest net assets as of December 2025: $279.70 Million USD
Based on the latest financial reports, GH Research PLC (GHRS) has net assets worth $279.70 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($288.23 Million) and total liabilities ($8.53 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $279.70 Million |
| % of Total Assets | 97.04% |
| Annual Growth Rate | 197.85% |
| 5-Year Change | 0.91% |
| 10-Year Change | N/A |
| Growth Volatility | 1753.48 |
GH Research PLC - Net Assets Trend (2019–2025)
This chart illustrates how GH Research PLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GH Research PLC (2019–2025)
The table below shows the annual net assets of GH Research PLC from 2019 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $279.70 Million | +56.30% |
| 2024-12-31 | $178.95 Million | -18.28% |
| 2023-12-31 | $218.97 Million | -12.35% |
| 2022-12-31 | $249.82 Million | -9.87% |
| 2021-12-31 | $277.18 Million | +4791.90% |
| 2020-12-31 | $5.67 Million | +1316.50% |
| 2019-12-31 | $400.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to GH Research PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15403600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.55 Million | 0.55% |
| Other Comprehensive Income | $1.52 Million | 0.54% |
| Other Components | $431.06 Million | 154.11% |
| Total Equity | $279.70 Million | 100.00% |
GH Research PLC Competitors by Market Cap
The table below lists competitors of GH Research PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangzhou Anyka Microelectronics Co. Ltd. A
SHG:688620
|
$353.08 Million |
|
Sichuan Kexin Mechanic Electric
SHE:300092
|
$353.13 Million |
|
Shanghai Shenda Co Ltd
SHG:600626
|
$353.38 Million |
|
Shanghai Yimin Commerce Group Co Ltd
SHG:600824
|
$353.40 Million |
|
Pegavision
TW:6491
|
$352.97 Million |
|
WAORF
PINK:WAORF
|
$352.92 Million |
|
Hunan Airbluer Environmental Protection Technology Co. Ltd.
SHE:301259
|
$352.91 Million |
|
Tejon Ranch Co
NYSE:TRC
|
$352.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GH Research PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 178,951,000 to 279,703,000, a change of 100,752,000 (56.3%).
- Net loss of 48,257,999 reduced equity.
- Other comprehensive income increased equity by 8,883,000.
- Other factors increased equity by 140,126,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-48.26 Million | -17.25% |
| Other Comprehensive Income | $8.88 Million | +3.18% |
| Other Changes | $140.13 Million | +50.1% |
| Total Change | $- | 56.30% |
Book Value vs Market Value Analysis
This analysis compares GH Research PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.35x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 1075.20x to 3.35x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.01 | $15.36 | x |
| 2020-12-31 | $0.19 | $15.36 | x |
| 2021-12-31 | $5.33 | $15.36 | x |
| 2022-12-31 | $4.80 | $15.36 | x |
| 2023-12-31 | $4.21 | $15.36 | x |
| 2024-12-31 | $3.44 | $15.36 | x |
| 2025-12-31 | $4.58 | $15.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GH Research PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -17.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.03x
- Recent ROE (-17.25%) is above the historical average (-21.85%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -77.50% | 0.00% | 0.00x | 1.26x | $-350.00K |
| 2020 | -7.87% | 0.00% | 0.00x | 1.04x | $-1.01 Million |
| 2021 | -3.32% | 0.00% | 0.00x | 1.01x | $-36.92 Million |
| 2022 | -8.99% | 0.00% | 0.00x | 1.02x | $-47.44 Million |
| 2023 | -16.25% | 0.00% | 0.00x | 1.03x | $-57.48 Million |
| 2024 | -21.77% | 0.00% | 0.00x | 1.05x | $-56.86 Million |
| 2025 | -17.25% | 0.00% | 0.00x | 1.03x | $-76.23 Million |
Industry Comparison
This section compares GH Research PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GH Research PLC (GHRS) | $279.70 Million | -77.50% | 0.03x | $353.01 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |